Tesamorelin vs MGF.

Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH/GRF 1-44), stabilized by a trans-3-hexenoic acid group attached to its N-terminus. It is one of the few research peptides in its class that holds full FDA approval, marketed as Egrifta (and the reformulated Egrifta SV / Egrifta WR) by Theratechnologies for a narrow, specific indication. Originally designated TH9507, it is a secretagogue rather than a hormone itself.

MGF is a splice variant of insulin-like growth factor 1 (IGF-1), designated IGF-1Ec in humans and IGF-1Eb in rodents, produced locally in skeletal muscle in response to mechanical loading or damage. The synthetic 'MGF' peptide that is sold and studied is the unique C-terminal E-domain (Ec) portion, not the full IGF-1 molecule. It was characterized largely by Geoffrey Goldspink's group, who proposed it as an autocrine and paracrine signal that activates muscle satellite cells. It remains a preclinical research compound with no approved use.

Tesamorelin binds the GHRH receptor on the anterior pituitary, stimulating the synthesis and pulsatile release of the body's own growth hormone (GH), which in turn raises hepatic and circulating insulin-like growth factor-1 (IGF-1). Because it works upstream by amplifying endogenous GH secretion, it largely preserves physiological feedback and pulsatility, unlike direct exogenous GH administration. The N-terminal hexenoyl modification confers resistance to degradation (including by dipeptidyl peptidase-IV) and extends its half-life relative to native GHRH. The downstream rise in GH/IGF-1 drives lipolysis, with a notable effect on visceral (intra-abdominal) adipose tissue.

The mechanistic hypothesis is that the MGF E-peptide, generated by a reading-frame shift in IGF-1 splicing after mechanical stress, activates satellite (muscle stem) cells to proliferate through a receptor thought to be distinct from the classical IGF-1 receptor. In this model MGF acts as a local kick-start for repair that precedes the mature IGF-1 which later drives differentiation. This mechanism is characterized in cell and animal models, and even there it is contested. Several independent laboratories have been unable to reproduce a direct proliferative effect of the isolated E-peptide.

Human evidence is unusually strong for one specific population: HIV patients with lipodystrophy. Two pivotal phase 3 randomized, placebo-controlled trials and their pooled analysis (Falutz et al., JAIDS 2010 and J Clin Endocrinol Metab 2010) showed roughly a 15-18% reduction in visceral adipose tissue over 26 weeks, with regain after discontinuation, supporting the FDA approval. Stanley et al. (JAMA 2014; PMID 25038357) and a randomized NAFLD trial (Stanley et al., Lancet HIV 2019; PMID 31611038) further demonstrated reductions in liver fat and a lower rate of fibrosis progression in HIV-associated fatty liver disease. Crucially, nearly all rigorous human data come from HIV-positive cohorts; use for general anti-aging, body recomposition, or NAFLD in HIV-negative people is extrapolation and has not been established in large controlled trials. Subcutaneous fat and total weight are largely unaffected, and effects reverse when treatment stops.

Early work from Goldspink and colleagues in the late 1990s and 2000s reported that mechanically induced IGF-1Ec/MGF expression tracked with muscle hypertrophy and repair, and some cell studies suggested the E-peptide activated satellite cells. The foundational experiments were expression studies rather than treatment studies. Rabbit skeletal muscle subjected to stretch and electrical stimulation showed a shift in IGF-1 splicing toward the alternative variant (PMID 10087355), and rodent muscle subjected to local damage showed the same splicing shift alongside satellite cell activation (PMID 12692175). Those designs establish a correlation between a mechanical stimulus and a transcript, in small animal groups, over short time courses, without blinding and without any peptide being administered. They do not show that giving the isolated E-peptide does anything. That story is directly challenged by Fornaro et al. in the American Journal of Physiology-Endocrinology and Metabolism (2014, PMID 24253050), who found that the MGF E-peptide at concentrations up to 500 ng/mL had no apparent effect on the proliferation of C2C12 myoblasts or primary human muscle stem cells, whereas mature IGF-1 did. That paper tested synthetic E-peptide obtained from more than one source and included the positive control that much of the earlier literature lacked, which is why it carries substantial weight against the original claim. The contrast with better-characterized molecules in the same family is stark. Mature IGF-1 has decades of receptor pharmacology behind it, and its recombinant form mecasermin is an approved drug for severe primary IGF-1 deficiency, with defined pharmacokinetics, a known hypoglycemia risk, and labeled monitoring requirements. MGF has none of that. There are essentially no controlled human trials of synthetic MGF for muscle growth or repair, no human pharmacokinetic data, no confirmed receptor, no toxicology package, and no outcome data of any kind. The evidence base is preclinical, mixed, and negative in key experiments.

The most consistent documented concerns are glucose-related: because it raises GH/IGF-1, tesamorelin can worsen insulin sensitivity and glucose tolerance, and IGF-1 levels are monitored in clinical practice. Common adverse effects in trials included injection-site reactions, arthralgia, myalgia, peripheral edema, and paresthesia; hypersensitivity reactions have occurred. It is contraindicated in pregnancy and in people with active malignancy, since elevated IGF-1 is a theoretical tumor-growth concern, and in those with disrupted hypothalamic-pituitary axis (e.g., pituitary tumor/surgery, head irradiation). The NIH LiverTox database assigns it a low likelihood of causing clinically apparent liver injury. Long-term safety beyond the trial windows, and safety in non-HIV populations, remains poorly characterized.

There is no meaningful human safety data for injected synthetic MGF. No clinical trial has been conducted, so there is no reported adverse-event profile, no established tolerated exposure, no immunogenicity assessment, and no chronic toxicology. Theoretical concerns follow from IGF-1 biology, including unregulated growth-factor signaling and the possibility of promoting proliferation of pre-existing tumor cells, although the isolated E-peptide's own activity is uncertain. That uncertainty cuts both ways. A peptide that does not measurably act on muscle stem cells in culture is unlikely to carry the full risk profile of mature IGF-1, but it is also not established to be inert, and the receptor it supposedly acts through has never been identified, which makes off-target prediction impossible. Injected peptides carry generic risks independent of the sequence, including local reactions, sterile abscess, infection from non-sterile preparation, and antibody formation against a foreign or modified sequence. Pegylated versions sold as PEG-MGF add a further unknown, since polyethylene glycol conjugates raise tissue-accumulation and anti-PEG antibody questions that have not been examined for this molecule at all. Material sold online as MGF or PEG-MGF is unregulated and of unverified identity and purity, and independent testing of the grey peptide market has repeatedly found mislabeled contents, under-filled vials, and bacterial contamination. Any legitimate study would require sterility and endotoxin testing of the material, immunogenicity monitoring, measurement of the IGF-1 axis, and exclusion of participants with a cancer history before first exposure. Human safety is uncharacterized.

FDA-approved (2010, as Egrifta; reformulated as Egrifta SV in 2019 and the F8 formulation Egrifta WR in 2023) solely to reduce excess visceral abdominal fat in HIV-infected adults with lipodystrophy. All other uses are off-label, and it is a prescription drug, not a dietary supplement.

MGF is not approved by the FDA or any regulator and holds no marketing authorization for any indication. It is sold only as a research chemical. Growth-factor peptides of this type are prohibited in sport by WADA.